What is AstraZeneca?
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines. Its primary therapeutic areas include Oncology and BioPharmaceuticals, encompassing treatments for Cardiovascular, Renal & Metabolism, and Respiratory & Immunology conditions. Headquartered in the United Kingdom, AstraZeneca is committed to pushing the boundaries of science to deliver life-changing medicines.
How much funding has AstraZeneca raised?
AstraZeneca has raised a total of $4.7B across 3 funding rounds:
Other Financing Round
$1B
Other Financing Round
$168M
Unspecified
$3.5B
Other Financing Round (2020): $1B with participation from Barda Ltd
Other Financing Round (2021): $168M led by Vaccitech Limited, Oxford Sciences Enterprises, M&G plc, and Gilead Sciences Inc
Unspecified (2024): $3.5B, investors not publicly disclosed
Key Investors in AstraZeneca
Barda Ltd
Barda Ltd is an investor participating in the company's financing rounds.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company with a strong partnership with the University of Oxford, focusing on building transformational businesses.
Gilead Sciences Inc
Gilead Sciences Inc is a biopharmaceutical company that invests in AstraZeneca's funding rounds.
What's next for AstraZeneca?
The substantial enterprise-level funding and recent strategic investment indicate AstraZeneca's robust financial standing and its continued commitment to innovation and growth within the biopharmaceutical sector. This capital infusion is likely to fuel further research and development initiatives, potentially leading to the advancement of new therapies and the expansion of its global market reach. The company's strategic focus on critical disease areas suggests a forward-looking approach to addressing unmet medical needs.
See full AstraZeneca company page
